Hypoxia promotes etoposide (VP-16) resistance in neuroblastoma CHP126 cells

Pharmazie

Volumn 65, Issue 1, 2010, Pages 51-56

  Duoduo, Wang ^a   Qionghua, Zhu ^a   Xiayan, Zhang ^a   Lei, Zhang ^a   Qiaojun, He ^a   Bo, Yang ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; CYCLIN B1; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 7; ETOPOSIDE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN P53;

APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL HYPOXIA; CONTROLLED STUDY; DRUG RESISTANCE; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; NEUROBLASTOMA CELL; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BLOTTING, WESTERN; BRAIN NEOPLASMS; CELL CYCLE; CELL HYPOXIA; CELL PROLIFERATION; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FLOW CYTOMETRY; GENES, P53; HUMANS; INDICATORS AND REAGENTS; NEOPLASM PROTEINS; NEUROBLASTOMA; SIGNAL TRANSDUCTION;

EID: 76149116189     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2010.9618     Document Type: Article

References (41)

1. Björck E, Ek S, Landgren O, Jerkeman M, Ehinger M, Björkholm M, Borrebaeck CA, Porwit-MacDonald A, Nordenskjöld M (2005) High expression of cyclin B1 predicts a favorable outcome in patients with follicular lymphoma. Blood 105: 2908-2915.
2. Boldt S, Weidle UH, Kolch W (2002) The role of MAPK pathways in the action of chemotherapeutic drugs. Carcinogenesis 23: 1831-1838.
3. Budman DR, Igwemezie LN, Kaul S, Behr J, Lichtman S, Schulman P, Vinciguerra V, Allen SL, Kolitz J, Hock K, et al. (1994) Phase I evaluation of a water-soluble etoposide prodrug, etoposide phosphate, given as a 5-minute infusion on days 1, 3, and 5 in patients with solid tumors. J Clin Oncol 12: 1902-1909.
4. Bussink J, Kaanders JH, van der Kogel AJ (2003) Tumor hypoxia at the micro-regional level: clinical relevance and predictive value of exogenous and endogenous hypoxic cell markers. Radiother Oncol 67: 3-15.
5. Chiu CC, Li CH, Ung MW, Norris MD, Xue C, Flemming C, Lunec J (2005) Etoposide (VP-16) elicits apoptosis following prolonged G2-M cell arrest in p53-mutated human non-small cell lung cancer cells. Cancer Lett 223: 249-258.
6. de Cremoux P, Jourdan-Da-Silva N, Couturier J, Tran-Perennou C, Schleiermacher G, Fehlbaum P, Doz F, Mosseri V, Delattre O, Klijanienko J, Vielh P, Michon J (2007) Role of chemotherapy resistance genes in outcome of neuroblastoma. Pediatr Blood Cancer 48: 311-317.
7. Duriez PJ, Shah GM (1997) Cleavage of poly(ADP-ribose) polymerase: a sensitive parameter to study cell death. Biochem Cell Biol 75: 337-349.
8. Glotzer M, Murray AW, Kirschner MW (1991) Cyclin is degraded by the ubiquitin pathway. Nature 349: 132-138.
9. Harrison L, Blackwell K (2004) Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy? Oncologist 9 (Suppl 5): 31-40.
10. Higginbottom K, Jahnke U, Newland AC Cotter FE, Allen PD (2007) New alternative phosphorylation sites on the cyclin dependent kinase 1/cyclin a complex in p53-deficient human cells treated with etoposide: possible association with etoposide-induced apoptosis. Apoptosis 12: 1847-1855.
11. Jahnke U, Higginbottom K, Newland AC, Cotter FE, Allen, PD (2007) Cell death in leukemia: passenger protein regulation by topoisomerase inhibitors. Biochem Biophys Res Commun 361: 928-933.
12. Karlsson J, Edsjö A, Påhlman S, Pettersson HM (2005) Multidrug-resistant neuroblastoma cells are responsive to arsenic trioxide at both normoxia and hypoxia. Mol Cancer Ther 4: 1128-1135.
13. Kaufmann WK (1998) Human topoisomerase II function, tyrosine phosphorylation and cell cycle checkpoints. Proc Soc Exp Biol Med 217: 327-334.
14. Krieg AJ, Hammond EM, Giaccia AJ (2006) Functional analysis of p53 binding under differential stresses. Mol Cell Biol 26: 7030-7045.
15. Lahav G, Rosenfeld N, Sigal A, Geva-Zatorsky N, Levine AJ, Elowitz MB, Alon U (2004) Dynamics of the p53-Mdm2 feedback loop in individual cells. Nat Genet 36: 147-150.
16. Larochelle S, Merrick KA, Terret ME, Wohlbold L, Barboza NM, Zhang C, Shokat KM, Jallepalli PV, Fisher RP (2007) Requirements for Cdk7 in the assembly of Cdk1/cyclin B and activation of Cdk2 revealed by chemical genetics in human cells. Mol Cell 25: 839-850.
17. Le QT, Denko NC, Giaccia AJ (2004) Hypoxic gene expression and metastasis. Cancer Metastasis Rev 23: 293-310.
18. Lee E, Lim SJ (2006) The association of increased lung resistance protein expression with acquired etoposide resistance in human H460 lung cancer cell lines. Arch Pharm Res. 29:1018-1023.
19. Lin YC, Wang FF (2008) Mechanisms underlying the pro-survival pathway of p53 in suppressing mitotic death induced by adriamycin. Cell Signal 20: 258-267.
20. Liu ZG, Zhao LN, Liu YW, Li TT, Fan DM, Chen JJ (2007) Activation of Cdc2 contributes to apoptosis in HPV E6 expressing human keratinocytes in response to therapeutic agents. J Mol Biol 374: 334-3345.
21. Lorca T, Labbé JC, Devault A Fesquet D, Capony JP, Cavadore JC, Le Bouffant F, Dorée M(1992) Dephosphorylation of cdc2 on threonine 161 is required for cdc2 kinase inactivation and normal anaphase. EMBO J 11: 2381-2390.
22. Lowis SP, Price L, Pearson AD, Newell DR, Cole M (1998) A study of the feasibility and accuracy of pharmacokinetically guided etoposide dosing in children. Br J Cancer 77: 2318-2323.
23. Marshall C (1999) How do small GTPase signal transduction pathways regulate cell cycle entry? Curr Opin Cell Biol 11: 732-736.
24. Matsuura K, Wakasugi M, Yamashita K, Matsunaga T (2008) Cleavage-mediated activation of Chk1 during apoptosis. J Biol Chem 283: 25485-25491.
25. Matthay KK, Villablanca JG, Seeger RC Stram DO, Harris RE, Ramsay NK, Swift P, Shimada H, Black CT, Brodeur GM, Gerbing RB, Reynolds CP (1999) Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 341: 1165-1173.
26. Moll UM, Petrenko O (2003) The MDM2-p53 interaction. Mol Cancer Res 1: 1001-1008.
27. Nam C, Yamauchi H, Nakayama H, Doi K (2006) Etoposide induces apoptosis and cell cycle arrest of neuroepithelial cells in a p53-related manner. Neurotoxicol Teratol 28: 664-672.
28. Ohnishi T (2005) The role of the p53 molecule in cancer therapies with radiation and/or hyperthermia. J Cancer Res Ther 1: 147-150.
29. Oren M, Damalas A, Gottlieb T, Michael D, Taplick J, Leal JF, Maya R, Moas M, Seger R, Taya Y, Ben-Ze'Ev A (2002) Regulation of p53: intricate loops and delicate balances. Ann N Y Acad Sci 973: 374-383.
30. Porter LA, Singh G, Lee JM (2000) Abundance of cyclin B1 regulates gamma-radiation-induced apoptosis. Blood 95: 2645-2650.
31. Sermeus A, Cosse JP, Crespin M, Mainfroid V, de Longueville F, Ninane N, Raes M, Remacle J, Michiels C (2008) Hypoxia induces protection against etoposide-induced apoptosis: molecular profiling of changes in gene expression and transcription factor activity. Mol Cancer 7: 27.
32. Shi L, Nishioka WK, Th'ng J, Bradbury EM, Litchfield DW, Greenberg AH (1994) Premature p34cdc2 activation required for apoptosis. Science 263: 1143-1145.
33. Tang D, Wu D, Hirao A, Lahti JM, Liu L, Mazza B, Kidd VJ, Mak TW, Ingram AJ (2002) ERK activation mediates cell cycle arrest and apoptosis after DNA damage independently of p53. J Biol Chem 277: 12710-12717.
34. Taylor WR, Stark GR (2001) Regulation of the G2/M transition by p53. Oncogene 20: 1803-1815.
35. Thornberry NA, Lazebnik Y (1998) Caspases: enemies within. Science. 281: 1312-1316.
36. Tweddle DA, Pearson AD, Haber M, Norris MD, Xue C, Flemming C, Lunec J (2003) The p53 pathway and its inactivation in neuroblastoma. Cancer Lett 197: 93-98.
37. Unruh A, Ressel A, Mohamed HG, Johnson RS, Nadrowitz R, Richter E, Katschinski DM, Wenger RH (2003) The hypoxia-inducible factor-1 alpha is a negative factor for tumor therapy. Oncogene 22: 3213-3220.
38. Wang J, Lv XW, Shi JP, Hu, XS (2007) Mechanisms involved in ceramide-induced cell cycle arrest in human hepatocarcinoma cells. World J Gastroenterol. 13: 1129-1134.
39. Wartenberg M, Ling FC, Müschen M, Klein F, Acker H, Gassmann M, Petrat K, Pütz V, Hescheler J, Sauer H (2003) Regulation of the multidrug resistance transporter P-glycoprotein in multicellular tumor spheroids by hypoxia-inducible factor (HIF-1) and reactive oxygen species. FASEB J 17: 503-505.
40. Yao SL, McKenna KA, Sharkis SJ, Bedi A (1996) Requirement of p34cdc2 kinase for apoptosis mediated by the Fas/APO-1 receptor and interleukin 1beta-converting enzyme-related proteases. Cancer Res 56: 4551-4555.
41. Yu J, Guo QL, You QD, Zhao L, Gu HY, Yang Y, Zhang HW, Tan Z, Wang X (2007) Gambogic acid-induced G2/M phase cell-cycle arrest via disturbing CDK7-mediated phosphorylation of CDC2/p34 in human gastric carcinoma BGC-823 cells. Carcinogenesis 28: 632-638.